Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

The "CC Chemokine Receptor Type 5 Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The CC ...

Popular weight-loss drug Wegovy maker Novo Nordisk expects high demand and acceptance for its anti-obesity drug, when ...

Stephen Hoge will now oversee vaccine sales at Moderna, per a Bloomberg report. Elsewhere, Intra-Cellular unveiled an ...

Canaccord raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $408 from $361 and keeps a Sell rating on the shares. The ...

From a technical perspective, Vertex Pharmaceuticals (VRTX) is looking like an interesting pick, as it just reached a key level of support. VRTX recently overtook the 50-day moving average, and this ...

Is India’s booming healthcare market part of your strategy, or are you overlooking a crucial opportunity? This is a question that U.S. healthcare companies should be pondering as India’s health and ...

with no options for the drug becoming available to patients in India in sight. The drug for CF (CFTR modulators), while under monopoly, continues to be unavailable in the country due to a lack of ...

Patients with rare diseases in India, like Saifullah Khalidi with spinal muscular atrophy (SMA), struggle to afford ...

RBC Capital raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $451 from $437 but keeps a Sector Perform rating on the ...

Patient advocates push for generic drug production to treat rare diseases, facing patent barriers and high costs.